Antibacterial Compositions with Avermectin and Melatonin for Demodex Blepharitis Treatment
Summary
USPTO published patent application US20260097059A1 covering pharmaceutical compositions for treating Demodex blepharitis. The compositions include avermectin compounds (such as ivermectin derivatives) and melatonin, with optional concentrations under 1 wt %. The application also discloses wipe devices incorporating these treatment compositions. Inventor Rolando Toyos filed the application on January 30, 2025, with publication on April 9, 2026.
What changed
USPTO published patent application US20260097059A1 for compositions and processes using avermectin compounds and melatonin to treat Demodex blepharitis, an inflammatory eye condition caused by parasitic mites. The application covers pharmaceutical compositions with avermectin at concentrations potentially below 1 wt %, as well as wipe devices incorporating the treatment composition. The application establishes priority rights from the January 30, 2025 filing date.
Pharmaceutical manufacturers developing treatments for blepharitis or other ocular conditions, and medical device companies producing therapeutic wipes for eye care, should review this patent for potential freedom-to-operate concerns. Healthcare providers researching Demodex-related eye conditions may benefit from monitoring this application's prosecution for its disclosure of potential treatment approaches.
What to do next
- Monitor patent prosecution for scope and potential challenges
- Assess freedom-to-operate implications for competing eye care products
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROCESSES AND COMPOSITIONS WITH ANTIBACTERIAL PROPERTIES FOR THE TREATMENT OF DEMODEX BLEPHARITIS
Application US20260097059A1 Kind: A1 Apr 09, 2026
Inventors
Rolando Toyos
Abstract
Provided herein are compositions for the prevention and treatment of demodex blepharitis in a subject and processes of treatment or prevention of demodex blepharitis. The compositions may include at least one avermectin compound selected from 5-O-demethyl-22,23-dihydroavermectin A1a or 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, or a combination thereof, and melatonin, wherein an aggregate concentration of the avermectin compound is optionally less than 1 wt %. Further devices are provided that include wipe including a woven or non-woven membrane and a treatment composition, the treatment composition including melatonin, one or more anti-microbial compounds, and optionally one or more pharmaceutically acceptable excipients and processes of treatment or prevention of demodex blepharitis in a subject using the wipe, alone or optionally further with the composition as provided herein.
CPC Classifications
A61K 31/7048 A61K 31/14 A61K 31/4045 A61P 17/00 A61P 33/14
Filing Date
2025-01-30
Application No.
19040993
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.